Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.69 |
| ▸ | F9 | P00740 | 2/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7630545 | 0.85 | EPHX2 (0.51) | EPHX2F9F10PTGDR2ROCK1 | |
| SCHEMBL7238310 | 0.83 | ROCK1 (0.47) | EPHX2F9F10PTGDR2ROCK1 | |
| SCHEMBL3833306 | 0.82 | EPHX2 (1.00) | EPHX2ROCK1ALDH1A1MAPT | |
| SCHEMBL6989729 | 0.77 | ROCK1 (0.53) | PTGDR2ROCK1ALDH1A1LMNAGRM4 | |
| SCHEMBL13492485 | 0.73 | ABL1 (0.73) | — | |
| SCHEMBL31589035 | 0.73 | EPHX2 (0.58) | EPHX2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL7238788 | 0.72 | USP8 (0.65) | EPHX2KDM4EALDH1A1MAPT | |
| SCHEMBL7234775 | 0.72 | EPHX2 (0.64) | EPHX2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL6991668 | 0.71 | RAB9A (0.62) | EPHX2ROCK1KDM4EALDH1A1MAPT | |
| SCHEMBL7232939 | 0.71 | EPHX2 (0.61) | EPHX2KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406892-B1 | PHENYL PYRAZOLE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-09-05 | — | — | EP | claimed |
| US-6890925-B2 | Methods of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-10 | — | — | US | claimed |
| US-20040092567-A1 | Methods of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 2004-05-13 | — | — | US | claimed |
| EP-1406892-A1 | PHENYL PYRAZOLE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-04-14 | — | — | EP | claimed |
| US-20030022929-A1 | Method of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-30 | — | — | US | claimed |
| WO-2003002555-A1 | METHODS OF USING SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-01-09 | — | — | WO | claimed |
| EP-1406892-B1 | PHENYL PYRAZOLE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-09-05 | — | — | EP | disclosed |
| US-6890925-B2 | Methods of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| US-6831082-B2 | 1-phenyl pyrazole derivatives; treating cardiovascular disease | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-12-14 | — | — | US | disclosed |
| US-20040092567-A1 | Methods of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 2004-05-13 | — | — | US | disclosed |
| EP-1406892-A1 | PHENYL PYRAZOLE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030022929-A1 | Method of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-30 | — | — | US | disclosed |
| US-6506747-B1 | Method of treating an inflammatory disease which comprises administering to a patient in need of such treatment-a N-(4-(5-Ethyl-3-pyridin-3-yl-pyrazol-1-yl)phenyl)pyridine-3-carboxamide; | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| WO-2003002555-A1 | METHODS OF USING SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-1999062885-A1 | SUBSTITUTED 1-(4-AMINOPHENYL)PYRAZOLES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022929-A1 | Method of using soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885F9 1597/4885F10 1244/4885 |
| US-20040092567-A1 | Methods of using soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885F9 2249/4885F10 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.